Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07ZKK
|
|||
Former ID |
DIB010311
|
|||
Drug Name |
131I-81C6
|
|||
Synonyms |
Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Brain cancer [ICD-11: 2A00] | Terminated | [1] | |
Company |
Duke University
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tenascin (TNC) | Target Info | . | [1], [2] |
KEGG Pathway | PI3K-Akt signaling pathway | |||
Focal adhesion | ||||
ECM-receptor interaction | ||||
MicroRNAs in cancer | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
Beta3 integrin cell surface interactions | ||||
Alpha9 beta1 integrin signaling events | ||||
Syndecan-4-mediated signaling events | ||||
Reactome | Integrin cell surface interactions | |||
Syndecan interactions | ||||
ECM proteoglycans | ||||
WikiPathways | TGF beta Signaling Pathway | |||
Focal Adhesion | ||||
Syndecan interactions | ||||
Extracellular matrix organization | ||||
Integrin cell surface interactions |
References | Top | |||
---|---|---|---|---|
REF 1 | Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502. | |||
REF 2 | A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 April; 10(2): 182-189. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.